Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy
Source abstract
Abstract
An overlay of local ablation and immunotherapies could be one of the promising approaches to treat solid tumors, but finding the synergistic combination is still challenging with immune tolerance. Herein, electric pulse responsive iron-oxide-nanocube clusters (IONCs) loaded with indoleamine 2,3-dioxygenase inhibitors (IDOi) are prepared for the enhancement of irreversible electroporation (IRE) cell killing and modulation of the tumor immunosuppressive microenvironment (TIM). IDOi-loaded-IONCs (IDOi-IONCs) show highly responsive movement upon the application of IRE electric pulses inducing local magnetic fields. In vitro and in vivo IRE cell-killing efficiency are significantly enhanced by the IDOi-IONCs. The IRE with IDOi-IONCs also triggers IDOi release from IONCs for TIM modulation. The enhanced cell death and local IDOi release of the IRE with IDOi-IONCs demonstrate a synergistic anticancer effect in vivo with overturning the TIM. The increased infiltration of CD8+ T cells and the elevated ratio of CD8+ T cells to regulatory T cells are confirmed after the IRE with IDOi-IONCs. Further, synergistic interaction between IRE and IDOi-modulated TIM resulted in enhanced elimination of primary and secondary tumors. This proof-of-concept work illustrates a robust modality to guide immune-modulating nanoparticle-mediated immuno-ablation cancer therapies that can be easily tailored to improve its therapeutic outcome.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Microbial Inactivation Methods · Molecular Communication and Nanonetworks · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States
Department of Biomedical Engineering, McCormick School of Engineering, Evanston, Illinois 60208, United States
Department of Bioengineering, University of Illinois at Chicago, Chicago, Illinois 60607, United States
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, United States
Funding
National Cancer Institute · National Institute of Biomedical Imaging and Bioengineering
References (56)
Show source-provided references
1. 10.1148/radiol.1413295810.1148/radiol.14132958 ↗
2. 10.1056/NEJMoa110858610.1056/NEJMoa1108586 ↗
3. 10.1038/s41467-019-13204-310.1038/s41467-019-13204-3 ↗
4. 10.1056/NEJMra160898610.1056/NEJMra1608986 ↗
5. 10.1148/radiol.201818134910.1148/radiol.2018181349 ↗
6. 10.1021/acsnano.0c0470110.1021/acsnano.0c04701 ↗
7. 10.1016/j.diii.2017.04.00810.1016/j.diii.2017.04.008 ↗
8. 10.3389/fimmu.2019.0228310.3389/fimmu.2019.02283 ↗
9. 10.1200/JCO.2019.37.15_suppl.e1424310.1200/JCO.2019.37.15_suppl.e14243 ↗
10. 10.1016/j.critrevonc.2018.06.01710.1016/j.critrevonc.2018.06.017 ↗
11. 10.1186/s40880-017-0216-510.1186/s40880-017-0216-5 ↗
12. 10.1080/2162402X.2017.137323110.1080/2162402X.2017.1373231 ↗
13. 10.1002/eji.20093948610.1002/eji.200939486 ↗
14. 10.1182/blood-2008-12-19507310.1182/blood-2008-12-195073 ↗
15. 10.1186/s13014-016-0693-810.1186/s13014-016-0693-8 ↗
16. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
17. 10.1021/jacs.9b1223210.1021/jacs.9b12232 ↗
18. 10.1021/acsmedchemlett.9b0034410.1021/acsmedchemlett.9b00344 ↗
19. 10.1021/acs.nanolett.0c0011310.1021/acs.nanolett.0c00113 ↗
20. 10.1038/nbt.418010.1038/nbt.4180 ↗
21. 10.1126/science.281.5380.119110.1126/science.281.5380.1191 ↗
22. 10.1182/blood-2009-09-24612410.1182/blood-2009-09-246124 ↗
23. 10.1038/s41568-019-0106-z10.1038/s41568-019-0106-z ↗
24. 10.1074/jbc.271.29.1724710.1074/jbc.271.29.17247 ↗
25. 10.1016/j.ejca.2017.01.01110.1016/j.ejca.2017.01.011 ↗
26. 10.1158/1078-0432.CCR-04-267110.1158/1078-0432.CCR-04-2671 ↗
27. 10.1158/1078-0432.CCR-05-196610.1158/1078-0432.CCR-05-1966 ↗
28. 10.1038/nrc367210.1038/nrc3672 ↗
29. 10.1148/radiol.201918232610.1148/radiol.2019182326 ↗
30. 10.1148/radiol.201717092010.1148/radiol.2017170920 ↗
31. 10.1021/acsmacrolett.5b0054510.1021/acsmacrolett.5b00545 ↗
32. 10.1016/j.jvir.2014.01.02810.1016/j.jvir.2014.01.028 ↗
33. 10.1146/annurev-bioeng-071813-10462210.1146/annurev-bioeng-071813-104622 ↗
34. 10.1002/jso.2428810.1002/jso.24288 ↗
35. 10.1016/j.surg.2013.06.00510.1016/j.surg.2013.06.005 ↗
36. 10.1166/jbn.2016.217410.1166/jbn.2016.2174 ↗
37. 10.1080/10717544.2018.144468310.1080/10717544.2018.1444683 ↗
38. 10.1038/s41467-019-08782-110.1038/s41467-019-08782-1 ↗
39. 10.1038/nri390210.1038/nri3902 ↗
40. 10.1038/srep2378110.1038/srep23781 ↗
41. 10.3892/ol.2017.640510.3892/ol.2017.6405 ↗
42. 10.1038/nmat259110.1038/nmat2591 ↗
43. 10.1039/D0CC03614E10.1039/D0CC03614E ↗
44. 10.1038/s41467-020-17380-510.1038/s41467-020-17380-5 ↗
45. 10.3390/cancers1111176310.3390/cancers11111763 ↗
46. 10.1007/s10495-019-01532-010.1007/s10495-019-01532-0 ↗
47. 10.1002/smll.20190437810.1002/smll.201904378 ↗
48. 10.1021/acs.nanolett.8b0140610.1021/acs.nanolett.8b01406 ↗
49. 10.1038/ni75810.1038/ni758 ↗
50. 10.1002/adma.20180300110.1002/adma.201803001 ↗
51. 10.1084/jem.2012084610.1084/jem.20120846 ↗
52. 10.1016/j.jvir.2018.07.00910.1016/j.jvir.2018.07.009 ↗
53. 10.1002/adma.20190415610.1002/adma.201904156 ↗
54. 10.1126/sciadv.aaw687010.1126/sciadv.aaw6870 ↗
55. 10.1021/acsami.6b0350510.1021/acsami.6b03505 ↗
56. 10.1021/acs.nanolett.8b0140610.1021/acs.nanolett.8b01406 ↗